| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 139 | 2024 | 1560 | 7.910 |
Why?
|
| Asparaginase | 35 | 2024 | 240 | 2.410 |
Why?
|
| Leukemia, Lymphoid | 48 | 1988 | 307 | 1.290 |
Why?
|
| Doxorubicin | 32 | 2018 | 2228 | 1.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 59 | 2024 | 11855 | 1.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2020 | 385 | 1.190 |
Why?
|
| Razoxane | 6 | 2012 | 43 | 1.120 |
Why?
|
| Antibiotics, Antineoplastic | 15 | 2016 | 679 | 1.040 |
Why?
|
| Cranial Irradiation | 13 | 2009 | 384 | 1.000 |
Why?
|
| Cardiotonic Agents | 7 | 2016 | 539 | 0.930 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2018 | 230 | 0.820 |
Why?
|
| Antineoplastic Agents | 45 | 2018 | 13635 | 0.740 |
Why?
|
| Child, Preschool | 164 | 2024 | 42478 | 0.730 |
Why?
|
| Dexamethasone | 15 | 2017 | 1963 | 0.720 |
Why?
|
| Child | 210 | 2024 | 80509 | 0.670 |
Why?
|
| Osteonecrosis | 6 | 2019 | 230 | 0.580 |
Why?
|
| Infant | 118 | 2021 | 36375 | 0.570 |
Why?
|
| Prednisone | 23 | 2018 | 1562 | 0.560 |
Why?
|
| Bone Marrow Transplantation | 19 | 2016 | 2729 | 0.510 |
Why?
|
| Wilms Tumor | 11 | 1994 | 378 | 0.490 |
Why?
|
| Methotrexate | 19 | 2018 | 1720 | 0.460 |
Why?
|
| Vincristine | 22 | 2018 | 1037 | 0.460 |
Why?
|
| Adolescent | 148 | 2024 | 88794 | 0.460 |
Why?
|
| Troponin T | 4 | 2012 | 785 | 0.450 |
Why?
|
| Survivors | 10 | 2016 | 2373 | 0.430 |
Why?
|
| Disease-Free Survival | 29 | 2023 | 6839 | 0.430 |
Why?
|
| Remission Induction | 14 | 2020 | 2410 | 0.410 |
Why?
|
| Polyethylene Glycols | 7 | 2021 | 1188 | 0.400 |
Why?
|
| Anthracyclines | 3 | 2014 | 284 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 11 | 2016 | 1609 | 0.340 |
Why?
|
| Proto-Oncogenes | 6 | 2003 | 320 | 0.340 |
Why?
|
| Neoplasm Proteins | 13 | 2018 | 3592 | 0.320 |
Why?
|
| Neoplasm, Residual | 7 | 2020 | 1009 | 0.320 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2013 | 1535 | 0.310 |
Why?
|
| Heart | 6 | 2012 | 4419 | 0.310 |
Why?
|
| Gene Expression Regulation, Leukemic | 8 | 2018 | 658 | 0.300 |
Why?
|
| Combined Modality Therapy | 34 | 2009 | 8529 | 0.290 |
Why?
|
| Neoplasms, Second Primary | 5 | 2011 | 1056 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2019 | 4521 | 0.280 |
Why?
|
| Humans | 286 | 2024 | 765823 | 0.280 |
Why?
|
| Survival Rate | 24 | 2021 | 12821 | 0.280 |
Why?
|
| Prednisolone | 4 | 2007 | 323 | 0.270 |
Why?
|
| Cardiomyopathies | 5 | 2014 | 2066 | 0.270 |
Why?
|
| Radiotherapy | 13 | 2007 | 1493 | 0.260 |
Why?
|
| Male | 163 | 2024 | 363740 | 0.260 |
Why?
|
| Burkitt Lymphoma | 8 | 2007 | 338 | 0.260 |
Why?
|
| Antiemetics | 6 | 1994 | 185 | 0.260 |
Why?
|
| Heart Diseases | 7 | 2015 | 2818 | 0.260 |
Why?
|
| Female | 163 | 2024 | 396050 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2014 | 1409 | 0.250 |
Why?
|
| Translocation, Genetic | 10 | 2004 | 1393 | 0.250 |
Why?
|
| Leukemia | 9 | 2016 | 1523 | 0.240 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2014 | 1150 | 0.240 |
Why?
|
| Prognosis | 46 | 2021 | 29915 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2018 | 5335 | 0.230 |
Why?
|
| Memory Disorders | 3 | 2012 | 1193 | 0.220 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 8 | 2018 | 309 | 0.220 |
Why?
|
| Neoplasms | 18 | 2015 | 22349 | 0.220 |
Why?
|
| Echocardiography | 9 | 2013 | 5042 | 0.220 |
Why?
|
| Venous Thromboembolism | 4 | 2024 | 1883 | 0.220 |
Why?
|
| Cardiovascular Agents | 3 | 2010 | 850 | 0.210 |
Why?
|
| Cardiotoxins | 2 | 2013 | 35 | 0.210 |
Why?
|
| Apoptosis | 10 | 2018 | 9512 | 0.210 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1736 | 0.210 |
Why?
|
| Cytarabine | 8 | 2014 | 696 | 0.210 |
Why?
|
| Radiation Injuries | 4 | 2004 | 1181 | 0.210 |
Why?
|
| Neoplasms, Radiation-Induced | 7 | 2007 | 540 | 0.210 |
Why?
|
| Infant, Newborn | 32 | 2016 | 26337 | 0.210 |
Why?
|
| Cognition Disorders | 4 | 2015 | 3966 | 0.200 |
Why?
|
| Kidney Neoplasms | 11 | 1994 | 4278 | 0.200 |
Why?
|
| Histone-Lysine N-Methyltransferase | 9 | 2018 | 697 | 0.200 |
Why?
|
| Follow-Up Studies | 37 | 2021 | 39226 | 0.190 |
Why?
|
| Cerebellar Neoplasms | 6 | 1995 | 571 | 0.190 |
Why?
|
| Peptide Fragments | 4 | 2014 | 5127 | 0.190 |
Why?
|
| Leukemia, B-Cell | 3 | 2012 | 86 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2011 | 3641 | 0.190 |
Why?
|
| Medulloblastoma | 6 | 1995 | 657 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1927 | 0.190 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2001 | 38 | 0.180 |
Why?
|
| Sequence Deletion | 3 | 2018 | 1493 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2003 | 533 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 1992 | 348 | 0.180 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 183 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 290 | 0.170 |
Why?
|
| Janus Kinase 2 | 2 | 2015 | 562 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 2 | 2018 | 230 | 0.170 |
Why?
|
| Clinical Protocols | 3 | 2011 | 1438 | 0.160 |
Why?
|
| Polymorphism, Genetic | 4 | 2013 | 4249 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 16040 | 0.160 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 5781 | 0.160 |
Why?
|
| Bone Marrow | 18 | 2006 | 2919 | 0.150 |
Why?
|
| Age Factors | 21 | 2019 | 18380 | 0.150 |
Why?
|
| Immunophenotyping | 9 | 2018 | 1865 | 0.150 |
Why?
|
| Vomiting | 6 | 1994 | 645 | 0.150 |
Why?
|
| Recurrence | 21 | 2014 | 8506 | 0.150 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 32 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2000 | 386 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 997 | 0.150 |
Why?
|
| Risk Factors | 31 | 2024 | 74853 | 0.150 |
Why?
|
| Nutrition Disorders | 1 | 2019 | 203 | 0.150 |
Why?
|
| Antigens, Neoplasm | 15 | 2005 | 1998 | 0.150 |
Why?
|
| Neuroblastoma | 6 | 1988 | 1264 | 0.140 |
Why?
|
| Central Nervous System Diseases | 6 | 2007 | 519 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2019 | 457 | 0.140 |
Why?
|
| Aspartate-Ammonia Ligase | 2 | 2014 | 18 | 0.140 |
Why?
|
| Treatment Outcome | 28 | 2018 | 65223 | 0.140 |
Why?
|
| Premedication | 1 | 2018 | 245 | 0.140 |
Why?
|
| Ventricular Function, Left | 9 | 2015 | 3931 | 0.140 |
Why?
|
| Mutation | 10 | 2018 | 30188 | 0.140 |
Why?
|
| Time Factors | 29 | 2015 | 40109 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2018 | 2839 | 0.140 |
Why?
|
| Thymidylate Synthase | 1 | 2016 | 73 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 7 | 2014 | 1352 | 0.140 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 7 | 2007 | 352 | 0.140 |
Why?
|
| Leukocyte Count | 12 | 2018 | 1603 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 10 | 0.130 |
Why?
|
| Cell Line, Tumor | 16 | 2018 | 17063 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2014 | 2655 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2014 | 2454 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 642 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 8 | 2016 | 6061 | 0.120 |
Why?
|
| Survival Analysis | 13 | 2018 | 10087 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2019 | 7846 | 0.120 |
Why?
|
| Escherichia coli | 6 | 2015 | 4211 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
| Gene Rearrangement | 6 | 2009 | 1144 | 0.120 |
Why?
|
| Quality of Life | 6 | 2023 | 13466 | 0.120 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2018 | 357 | 0.120 |
Why?
|
| Receptors, Laminin | 1 | 2014 | 26 | 0.120 |
Why?
|
| Drug Administration Schedule | 13 | 2014 | 4849 | 0.120 |
Why?
|
| Cell Proliferation | 8 | 2014 | 10428 | 0.120 |
Why?
|
| Injections, Spinal | 8 | 2007 | 308 | 0.120 |
Why?
|
| Gene Duplication | 2 | 2014 | 317 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 227 | 0.120 |
Why?
|
| Gene Deletion | 4 | 2011 | 2667 | 0.110 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 2005 | 111 | 0.110 |
Why?
|
| HMGN1 Protein | 1 | 2014 | 27 | 0.110 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 15645 | 0.110 |
Why?
|
| Young Adult | 18 | 2024 | 59849 | 0.110 |
Why?
|
| DNA, Intergenic | 1 | 2014 | 108 | 0.110 |
Why?
|
| Adult | 65 | 2024 | 223055 | 0.110 |
Why?
|
| Carcinoma | 3 | 2016 | 2312 | 0.110 |
Why?
|
| Genome-Wide Association Study | 4 | 2024 | 12800 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2018 | 9372 | 0.110 |
Why?
|
| Fractures, Bone | 4 | 2024 | 2041 | 0.110 |
Why?
|
| Risk | 13 | 2011 | 9600 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2014 | 268 | 0.110 |
Why?
|
| B-Lymphocytes | 8 | 2014 | 4779 | 0.110 |
Why?
|
| Spinal Cord Neoplasms | 3 | 1991 | 258 | 0.110 |
Why?
|
| Bone Marrow Purging | 1 | 1993 | 108 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 772 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2014 | 262 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2016 | 3606 | 0.100 |
Why?
|
| Nutritional Status | 2 | 2019 | 1620 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 645 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2007 | 918 | 0.100 |
Why?
|
| Pectobacterium carotovorum | 1 | 1992 | 8 | 0.100 |
Why?
|
| Drug Hypersensitivity | 3 | 2010 | 902 | 0.100 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2003 | 166 | 0.100 |
Why?
|
| bcl-X Protein | 1 | 2014 | 414 | 0.100 |
Why?
|
| Cognition | 4 | 2013 | 7045 | 0.100 |
Why?
|
| Health Status | 3 | 2018 | 4084 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2015 | 707 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2015 | 270 | 0.100 |
Why?
|
| Ribosomal Proteins | 1 | 2014 | 366 | 0.100 |
Why?
|
| Signal Transduction | 10 | 2018 | 23588 | 0.100 |
Why?
|
| Antioxidants | 1 | 2020 | 1670 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2010 | 474 | 0.100 |
Why?
|
| Resorcinols | 1 | 2012 | 41 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2018 | 10723 | 0.100 |
Why?
|
| Hemochromatosis | 1 | 2013 | 175 | 0.100 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 30 | 0.100 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2011 | 11 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 1981 | 0.090 |
Why?
|
| Aminopyridines | 1 | 2015 | 576 | 0.090 |
Why?
|
| Erwinia | 2 | 2010 | 22 | 0.090 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 710 | 0.090 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 1738 | 0.090 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 2226 | 0.090 |
Why?
|
| Transplantation, Autologous | 10 | 1997 | 2126 | 0.090 |
Why?
|
| Incidence | 10 | 2024 | 21501 | 0.090 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2011 | 55 | 0.090 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2010 | 15 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2013 | 4562 | 0.090 |
Why?
|
| Bacteremia | 1 | 2018 | 988 | 0.090 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2011 | 94 | 0.090 |
Why?
|
| Chromosome Aberrations | 7 | 2012 | 1776 | 0.090 |
Why?
|
| Transcription Factors | 5 | 2003 | 12122 | 0.090 |
Why?
|
| Maxillofacial Development | 1 | 1990 | 87 | 0.090 |
Why?
|
| Tooth Diseases | 1 | 1990 | 73 | 0.090 |
Why?
|
| Neuropsychological Tests | 8 | 2015 | 7119 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 869 | 0.090 |
Why?
|
| Isoxazoles | 1 | 2012 | 233 | 0.090 |
Why?
|
| Glucocorticoids | 5 | 2009 | 2132 | 0.090 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2011 | 148 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2015 | 863 | 0.080 |
Why?
|
| Diet | 3 | 2019 | 8085 | 0.080 |
Why?
|
| Cell Survival | 7 | 2011 | 5747 | 0.080 |
Why?
|
| Down Syndrome | 1 | 2018 | 915 | 0.080 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 3418 | 0.080 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2010 | 85 | 0.080 |
Why?
|
| Codon, Terminator | 1 | 2010 | 125 | 0.080 |
Why?
|
| Lysine | 1 | 2014 | 993 | 0.080 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 334 | 0.080 |
Why?
|
| T-Lymphocytes | 13 | 2018 | 10262 | 0.080 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2009 | 133 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2005 | 2136 | 0.080 |
Why?
|
| Hypertension, Renal | 1 | 1989 | 135 | 0.080 |
Why?
|
| Histones | 3 | 2014 | 2592 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 422 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 1130 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 1856 | 0.080 |
Why?
|
| Pharmacogenetics | 3 | 2015 | 682 | 0.080 |
Why?
|
| Karyotyping | 6 | 2014 | 1176 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1056 | 0.080 |
Why?
|
| American Heart Association | 1 | 2013 | 1046 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1137 | 0.080 |
Why?
|
| Ploidies | 4 | 1994 | 287 | 0.070 |
Why?
|
| Energy Intake | 1 | 2016 | 2141 | 0.070 |
Why?
|
| Behavior | 1 | 2011 | 535 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2011 | 297 | 0.070 |
Why?
|
| Cytogenetics | 3 | 2005 | 197 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2011 | 403 | 0.070 |
Why?
|
| Risk Assessment | 6 | 2018 | 24278 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2003 | 412 | 0.070 |
Why?
|
| Thrombosis | 1 | 2022 | 2956 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 1365 | 0.070 |
Why?
|
| Anticoagulants | 3 | 2022 | 4862 | 0.070 |
Why?
|
| DNA, Neoplasm | 7 | 1997 | 1740 | 0.070 |
Why?
|
| Central Nervous System | 4 | 2002 | 1342 | 0.070 |
Why?
|
| Nausea | 4 | 1994 | 677 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 2007 | 112 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2003 | 1621 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2014 | 228 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1881 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2007 | 169 | 0.070 |
Why?
|
| Brain Neoplasms | 12 | 1996 | 9069 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 2045 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 10 | 1988 | 9241 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 8601 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1895 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 2878 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2057 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2057 | 0.070 |
Why?
|
| Homozygote | 3 | 2015 | 1774 | 0.070 |
Why?
|
| Mice, Inbred NOD | 4 | 2016 | 1837 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2005 | 1801 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6508 | 0.070 |
Why?
|
| Gene Expression Profiling | 8 | 2016 | 9520 | 0.060 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2006 | 67 | 0.060 |
Why?
|
| Acute Disease | 11 | 2003 | 7237 | 0.060 |
Why?
|
| Genotype | 6 | 2017 | 13023 | 0.060 |
Why?
|
| Immunoblotting | 4 | 2012 | 1643 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2235 | 0.060 |
Why?
|
| Sepsis | 1 | 2000 | 2603 | 0.060 |
Why?
|
| Staurosporine | 2 | 2005 | 240 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2017 | 3623 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 1990 | 588 | 0.060 |
Why?
|
| Endothelium | 2 | 2006 | 768 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2012 | 615 | 0.060 |
Why?
|
| Sulfamethoxazole | 1 | 1985 | 50 | 0.060 |
Why?
|
| Immunization, Passive | 4 | 1984 | 616 | 0.060 |
Why?
|
| Base Sequence | 8 | 2014 | 12402 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2012 | 2586 | 0.060 |
Why?
|
| Chromosomes, Human, 6-12 and X | 2 | 1984 | 70 | 0.060 |
Why?
|
| Trimethoprim | 1 | 1985 | 79 | 0.060 |
Why?
|
| Interleukin-7 | 2 | 2003 | 147 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 878 | 0.060 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 9594 | 0.060 |
Why?
|
| Cohort Studies | 11 | 2020 | 41643 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 1731 | 0.060 |
Why?
|
| Phenanthridines | 2 | 1981 | 49 | 0.060 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12056 | 0.060 |
Why?
|
| Clinical Trials as Topic | 13 | 2010 | 8039 | 0.060 |
Why?
|
| Mitochondria | 3 | 2018 | 3670 | 0.060 |
Why?
|
| Remission, Spontaneous | 9 | 1980 | 384 | 0.060 |
Why?
|
| Leukemia, Experimental | 2 | 2016 | 224 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 285 | 0.060 |
Why?
|
| Parents | 2 | 2016 | 3590 | 0.060 |
Why?
|
| Myocardial Contraction | 6 | 2015 | 1516 | 0.060 |
Why?
|
| Gene Silencing | 2 | 2014 | 1505 | 0.060 |
Why?
|
| Haplotypes | 3 | 2019 | 2728 | 0.060 |
Why?
|
| Enalapril | 2 | 2005 | 317 | 0.060 |
Why?
|
| Canada | 3 | 2015 | 2119 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2016 | 2190 | 0.060 |
Why?
|
| Body Height | 3 | 2005 | 1561 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 283 | 0.060 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2004 | 37 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1273 | 0.060 |
Why?
|
| Neoplasm Staging | 9 | 2013 | 11205 | 0.060 |
Why?
|
| Life Tables | 3 | 1996 | 366 | 0.060 |
Why?
|
| Chemokines, CC | 2 | 2003 | 285 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3139 | 0.060 |
Why?
|
| Drug Therapy, Combination | 12 | 2006 | 6304 | 0.050 |
Why?
|
| Leukemia, Myeloid | 5 | 2001 | 696 | 0.050 |
Why?
|
| DNA Primers | 4 | 2014 | 2823 | 0.050 |
Why?
|
| Sirolimus | 2 | 2011 | 1544 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 1118 | 0.050 |
Why?
|
| Salvage Therapy | 3 | 2002 | 1272 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 2794 | 0.050 |
Why?
|
| Meningeal Neoplasms | 4 | 2007 | 1253 | 0.050 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 102 | 0.050 |
Why?
|
| Ribonucleosides | 4 | 1985 | 79 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 419 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2004 | 380 | 0.050 |
Why?
|
| Gene Expression | 4 | 2014 | 7581 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 5692 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 1020 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 1994 | 3832 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2005 | 1511 | 0.050 |
Why?
|
| Langerhans Cells | 1 | 2003 | 170 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 5753 | 0.050 |
Why?
|
| Heart Ventricles | 2 | 2012 | 3832 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2009 | 1087 | 0.050 |
Why?
|
| Complement System Proteins | 5 | 1988 | 714 | 0.050 |
Why?
|
| Alleles | 4 | 2017 | 6893 | 0.050 |
Why?
|
| Phosphorylation | 5 | 2016 | 8278 | 0.050 |
Why?
|
| Cardiology | 1 | 2013 | 1700 | 0.050 |
Why?
|
| Eye Diseases | 1 | 1988 | 659 | 0.050 |
Why?
|
| Electron Transport Complex IV | 2 | 2016 | 188 | 0.050 |
Why?
|
| Lactose | 1 | 1982 | 95 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2921 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 10383 | 0.050 |
Why?
|
| Daunorubicin | 2 | 1984 | 157 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 3794 | 0.050 |
Why?
|
| Sex Factors | 7 | 2016 | 10607 | 0.050 |
Why?
|
| Sarcoidosis | 1 | 2007 | 534 | 0.050 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2003 | 169 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 1982 | 135 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2004 | 648 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 723 | 0.050 |
Why?
|
| Prospective Studies | 11 | 2020 | 54798 | 0.050 |
Why?
|
| Bone Neoplasms | 2 | 1991 | 2562 | 0.050 |
Why?
|
| Cyclophosphamide | 5 | 1988 | 2224 | 0.050 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 17595 | 0.040 |
Why?
|
| Administration, Oral | 5 | 2016 | 4018 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 4056 | 0.040 |
Why?
|
| Hodgkin Disease | 2 | 2008 | 1383 | 0.040 |
Why?
|
| Oncogenes | 2 | 2018 | 1233 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2011 | 2971 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 3815 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2015 | 4543 | 0.040 |
Why?
|
| Prochlorperazine | 1 | 1980 | 16 | 0.040 |
Why?
|
| Ependymoma | 2 | 1995 | 310 | 0.040 |
Why?
|
| Mice | 14 | 2016 | 81788 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2005 | 639 | 0.040 |
Why?
|
| Quebec | 1 | 2020 | 140 | 0.040 |
Why?
|
| Acetylation | 2 | 2014 | 1056 | 0.040 |
Why?
|
| DNA | 3 | 2009 | 7197 | 0.040 |
Why?
|
| Animals | 20 | 2018 | 168730 | 0.040 |
Why?
|
| Cell Differentiation | 5 | 2011 | 11643 | 0.040 |
Why?
|
| Flow Cytometry | 5 | 2018 | 5879 | 0.040 |
Why?
|
| Neprilysin | 4 | 1988 | 484 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3851 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2016 | 6204 | 0.040 |
Why?
|
| Random Allocation | 3 | 2016 | 2394 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2001 | 404 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 651 | 0.040 |
Why?
|
| Pain, Intractable | 1 | 1981 | 132 | 0.040 |
Why?
|
| Growth | 1 | 1982 | 365 | 0.040 |
Why?
|
| Intelligence Tests | 2 | 1992 | 504 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 4046 | 0.040 |
Why?
|
| Hippocampus | 1 | 2012 | 3774 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2005 | 1514 | 0.040 |
Why?
|
| Transplantation, Homologous | 4 | 2016 | 4858 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 313 | 0.040 |
Why?
|
| Fractures, Spontaneous | 1 | 2001 | 230 | 0.040 |
Why?
|
| Mice, SCID | 3 | 2014 | 2627 | 0.040 |
Why?
|
| Antigens, Surface | 3 | 1981 | 1617 | 0.040 |
Why?
|
| Mechlorethamine | 3 | 1989 | 129 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7476 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2000 | 432 | 0.040 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2005 | 616 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2015 | 1751 | 0.040 |
Why?
|
| Retrospective Studies | 17 | 2020 | 81505 | 0.040 |
Why?
|
| Phenotype | 9 | 2016 | 16706 | 0.040 |
Why?
|
| Thyroid Neoplasms | 2 | 1990 | 2354 | 0.040 |
Why?
|
| Bacterial Infections | 2 | 1985 | 1387 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2000 | 451 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 3 | 2006 | 2629 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5302 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2005 | 1375 | 0.040 |
Why?
|
| Coformycin | 3 | 1982 | 11 | 0.040 |
Why?
|
| Radiotherapy Dosage | 5 | 1993 | 2863 | 0.040 |
Why?
|
| Leucovorin | 1 | 2000 | 642 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 2 | 2005 | 962 | 0.040 |
Why?
|
| Meningioma | 1 | 2007 | 1222 | 0.040 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 239 | 0.040 |
Why?
|
| Philadelphia Chromosome | 2 | 2007 | 119 | 0.040 |
Why?
|
| Heart Failure | 5 | 2012 | 11838 | 0.040 |
Why?
|
| Middle Aged | 20 | 2024 | 223016 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 5 | 2007 | 6110 | 0.040 |
Why?
|
| Janus Kinase 3 | 2 | 2011 | 75 | 0.040 |
Why?
|
| Preleukemia | 1 | 1997 | 34 | 0.040 |
Why?
|
| Antigens, CD | 4 | 2018 | 4020 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4587 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2000 | 339 | 0.040 |
Why?
|
| Body Weight | 2 | 2003 | 4624 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1043 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3656 | 0.030 |
Why?
|
| Genomics | 2 | 2018 | 5926 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 3 | 1988 | 226 | 0.030 |
Why?
|
| Eye Neoplasms | 1 | 1979 | 305 | 0.030 |
Why?
|
| Lymphocytes | 5 | 1994 | 2601 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 12520 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 211 | 0.030 |
Why?
|
| Nurse-Patient Relations | 1 | 2016 | 101 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1551 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 2137 | 0.030 |
Why?
|
| Drug Evaluation | 7 | 1985 | 641 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 116 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1997 | 592 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 844 | 0.030 |
Why?
|
| Naphthacenes | 2 | 1986 | 7 | 0.030 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 11033 | 0.030 |
Why?
|
| Clonal Anergy | 1 | 1996 | 169 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2001 | 3406 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 4772 | 0.030 |
Why?
|
| Injections, Intramuscular | 2 | 2015 | 553 | 0.030 |
Why?
|
| Annexin A5 | 2 | 2007 | 102 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 895 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2018 | 504 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2003 | 496 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2000 | 1834 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 1995 | 913 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2001 | 1250 | 0.030 |
Why?
|
| Cranial Fossa, Posterior | 2 | 1995 | 134 | 0.030 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2741 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
| Metoclopramide | 1 | 1994 | 51 | 0.030 |
Why?
|
| Phenothiazines | 1 | 1994 | 60 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 150 | 0.030 |
Why?
|
| Reticular Formation | 1 | 1994 | 60 | 0.030 |
Why?
|
| Cisplatin | 4 | 1989 | 1653 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 350 | 0.030 |
Why?
|
| Zebrafish | 2 | 2018 | 3034 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 416 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1980 | 710 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2014 | 82 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2009 | 6607 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 2001 | 2412 | 0.030 |
Why?
|
| Pituitary Irradiation | 1 | 1994 | 14 | 0.030 |
Why?
|
| Ganglioneuroma | 2 | 1984 | 53 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 13402 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1994 | 71 | 0.030 |
Why?
|
| Serotonin Antagonists | 1 | 1994 | 146 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2014 | 117 | 0.030 |
Why?
|
| Troponin | 1 | 1997 | 533 | 0.030 |
Why?
|
| Genes, Wilms Tumor | 1 | 1994 | 92 | 0.030 |
Why?
|
| Isoantigens | 1 | 1996 | 562 | 0.030 |
Why?
|
| Lymph Nodes | 3 | 1984 | 3449 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 360 | 0.030 |
Why?
|
| Genome, Human | 1 | 2007 | 4445 | 0.030 |
Why?
|
| Eye | 1 | 1978 | 710 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 2 | 1988 | 282 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
| Phytotherapy | 1 | 1975 | 298 | 0.030 |
Why?
|
| Immune Sera | 3 | 1984 | 601 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 1990 | 4416 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 1994 | 317 | 0.030 |
Why?
|
| United States | 7 | 2021 | 72896 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2011 | 1240 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2002 | 2033 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2000 | 1258 | 0.030 |
Why?
|
| Procarbazine | 2 | 1989 | 172 | 0.030 |
Why?
|
| Nephrectomy | 2 | 1990 | 927 | 0.030 |
Why?
|
| Educational Status | 2 | 2008 | 2511 | 0.030 |
Why?
|
| Receptors, Steroid | 2 | 1984 | 155 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2001 | 1944 | 0.030 |
Why?
|
| Camptothecin | 1 | 1996 | 598 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2005 | 2511 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2000 | 1405 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2020 | 8725 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 4404 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 446 | 0.020 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1992 | 40 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2011 | 0.020 |
Why?
|
| Cell Movement | 2 | 2001 | 5190 | 0.020 |
Why?
|
| Overweight | 1 | 2023 | 2443 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2014 | 780 | 0.020 |
Why?
|
| DNA Mutational Analysis | 3 | 2005 | 4110 | 0.020 |
Why?
|
| Binding Sites | 2 | 2014 | 5999 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 430 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1992 | 89 | 0.020 |
Why?
|
| Piperazines | 2 | 2016 | 2546 | 0.020 |
Why?
|
| Neck | 1 | 2016 | 734 | 0.020 |
Why?
|
| Cell Lineage | 2 | 2016 | 2573 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 4639 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 138 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 18064 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2011 | 40 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 2 | 1984 | 308 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 1991 | 134 | 0.020 |
Why?
|
| Methylation | 1 | 2014 | 1075 | 0.020 |
Why?
|
| Dental Caries | 1 | 1995 | 429 | 0.020 |
Why?
|
| Exons | 2 | 2014 | 2391 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 1994 | 551 | 0.020 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 1990 | 24 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2011 | 115 | 0.020 |
Why?
|
| Craniopharyngioma | 1 | 1994 | 276 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 2013 | 12767 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 1992 | 167 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2012 | 258 | 0.020 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1990 | 43 | 0.020 |
Why?
|
| Logistic Models | 2 | 2004 | 13266 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2018 | 1611 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 148 | 0.020 |
Why?
|
| Odontogenesis | 1 | 1990 | 64 | 0.020 |
Why?
|
| Chromosome Deletion | 2 | 1994 | 1385 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 5786 | 0.020 |
Why?
|
| Health Literacy | 1 | 2016 | 465 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2011 | 68 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 1992 | 158 | 0.020 |
Why?
|
| Nervous System | 1 | 1994 | 542 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 292 | 0.020 |
Why?
|
| Marriage | 2 | 2008 | 351 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2014 | 494 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 713 | 0.020 |
Why?
|
| Tooth Root | 1 | 1990 | 161 | 0.020 |
Why?
|
| Regression Analysis | 3 | 2011 | 6320 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 124 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1992 | 242 | 0.020 |
Why?
|
| Occupations | 1 | 1992 | 516 | 0.020 |
Why?
|
| Maple Syrup Urine Disease | 1 | 1969 | 41 | 0.020 |
Why?
|
| Thyrotoxicosis | 1 | 1990 | 85 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1985 | 3183 | 0.020 |
Why?
|
| Oral Health | 1 | 1995 | 493 | 0.020 |
Why?
|
| Oximes | 1 | 1991 | 305 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 1393 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2219 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 427 | 0.020 |
Why?
|
| Transfection | 2 | 2011 | 5742 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2018 | 4133 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2006 | 2074 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2011 | 2919 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 726 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2012 | 454 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 1989 | 126 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1984 | 2470 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2013 | 634 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 380 | 0.020 |
Why?
|
| Cannabis | 1 | 1975 | 446 | 0.020 |
Why?
|
| Aged | 12 | 2023 | 171178 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2011 | 576 | 0.020 |
Why?
|
| Chromosome Disorders | 2 | 1989 | 498 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 7599 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2023 | 13041 | 0.020 |
Why?
|
| Heterozygote | 1 | 2015 | 2795 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1969 | 161 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 1997 | 1892 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 770 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5076 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 483 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1996 | 1811 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2003 | 868 | 0.020 |
Why?
|
| Insurance, Health | 2 | 2008 | 2521 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22227 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1164 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2012 | 1226 | 0.020 |
Why?
|
| Choroid Plexus | 1 | 1990 | 250 | 0.020 |
Why?
|
| Retinal Hemorrhage | 2 | 1979 | 97 | 0.020 |
Why?
|
| Boston | 2 | 2016 | 9336 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 577 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3716 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 88 | 0.020 |
Why?
|
| Anemia | 1 | 1977 | 1510 | 0.020 |
Why?
|
| Ultrasonography | 3 | 2010 | 5995 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 1988 | 438 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 960 | 0.020 |
Why?
|
| Kidney Diseases | 2 | 1988 | 2097 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 1988 | 164 | 0.020 |
Why?
|
| Brain | 5 | 1995 | 27178 | 0.020 |
Why?
|
| Cat Diseases | 2 | 1984 | 32 | 0.020 |
Why?
|
| Intelligence | 1 | 1992 | 922 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1991 | 13446 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 1166 | 0.020 |
Why?
|
| Myocardium | 2 | 1997 | 4763 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1134 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1081 | 0.020 |
Why?
|
| Diploidy | 2 | 2003 | 141 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1985 | 2884 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1996 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1600 | 0.020 |
Why?
|
| Interleukin-4 | 2 | 2003 | 1162 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2014 | 4424 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 1253 | 0.020 |
Why?
|
| Dog Diseases | 2 | 1984 | 142 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2331 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1991 | 1145 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1325 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 3 | 2012 | 6219 | 0.020 |
Why?
|
| Dactinomycin | 3 | 1984 | 304 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 779 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1898 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5018 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1986 | 148 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1988 | 605 | 0.020 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2018 | 3464 | 0.020 |
Why?
|
| Clone Cells | 3 | 2003 | 1671 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 92 | 0.020 |
Why?
|
| Suspensions | 1 | 1985 | 68 | 0.020 |
Why?
|
| Antibody Formation | 2 | 1994 | 1391 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 223 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 207 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 1994 | 1322 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1794 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 1740 | 0.010 |
Why?
|
| Mitomycins | 1 | 1984 | 45 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2017 | 9653 | 0.010 |
Why?
|
| Age Distribution | 1 | 2011 | 2865 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 91 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1982 | 395 | 0.010 |
Why?
|
| Stroke Volume | 3 | 2015 | 5594 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 26276 | 0.010 |
Why?
|
| Cells, Cultured | 3 | 2014 | 18970 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2011 | 3612 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2822 | 0.010 |
Why?
|
| Quinazolines | 1 | 2011 | 1365 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 22323 | 0.010 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 1984 | 45 | 0.010 |
Why?
|
| Immunoglobulins | 2 | 1984 | 852 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1984 | 370 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1969 | 587 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 684 | 0.010 |
Why?
|
| Brain Damage, Chronic | 2 | 1995 | 265 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 1489 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2006 | 938 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1984 | 548 | 0.010 |
Why?
|
| VDJ Recombinases | 1 | 2004 | 84 | 0.010 |
Why?
|
| Cataract | 2 | 1988 | 837 | 0.010 |
Why?
|
| Neisseria meningitidis | 1 | 1984 | 111 | 0.010 |
Why?
|
| Haemophilus influenzae | 1 | 1984 | 177 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1997 | 3802 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2005 | 608 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3104 | 0.010 |
Why?
|
| Mitomycin | 1 | 1984 | 261 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 2626 | 0.010 |
Why?
|
| Ribavirin | 1 | 1985 | 395 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2015 | 2339 | 0.010 |
Why?
|
| Osteosarcoma | 2 | 1995 | 909 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1995 | 2649 | 0.010 |
Why?
|
| Globins | 1 | 1984 | 406 | 0.010 |
Why?
|
| Syndrome | 2 | 2005 | 3269 | 0.010 |
Why?
|
| Eye Color | 1 | 1983 | 35 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 121 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 2005 | 253 | 0.010 |
Why?
|
| Chemokine CCL20 | 1 | 2003 | 64 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 3272 | 0.010 |
Why?
|
| Homeodomain Proteins | 2 | 2003 | 2427 | 0.010 |
Why?
|
| Receptors, CCR7 | 1 | 2003 | 104 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
| Horner Syndrome | 1 | 1983 | 35 | 0.010 |
Why?
|
| Receptors, CCR6 | 1 | 2003 | 73 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 871 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 314 | 0.010 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 15398 | 0.010 |
Why?
|
| Disease Progression | 3 | 2005 | 13613 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2391 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1984 | 285 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2011 | 2487 | 0.010 |
Why?
|
| Lymphocyte Activation | 3 | 2005 | 5501 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1984 | 1306 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 474 | 0.010 |
Why?
|
| Orbital Neoplasms | 1 | 1984 | 222 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1981 | 27 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1984 | 399 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14644 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2003 | 378 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 479 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1984 | 267 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1981 | 64 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 350 | 0.010 |
Why?
|
| Motion Sickness | 1 | 1982 | 33 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2005 | 824 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3317 | 0.010 |
Why?
|
| Chemokine CCL22 | 1 | 2001 | 27 | 0.010 |
Why?
|
| Computer Systems | 1 | 2003 | 466 | 0.010 |
Why?
|
| Pedigree | 2 | 2005 | 4528 | 0.010 |
Why?
|
| Chemokine CCL17 | 1 | 2001 | 25 | 0.010 |
Why?
|
| Scopolamine | 1 | 1982 | 92 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1984 | 552 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2003 | 423 | 0.010 |
Why?
|
| Employment | 1 | 2008 | 1106 | 0.010 |
Why?
|
| Substantia Gelatinosa | 1 | 1981 | 11 | 0.010 |
Why?
|
| Laparotomy | 1 | 1984 | 460 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1984 | 576 | 0.010 |
Why?
|
| Sarcoma | 2 | 1990 | 1800 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 9548 | 0.010 |
Why?
|
| CpG Islands | 1 | 2006 | 1207 | 0.010 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1981 | 177 | 0.010 |
Why?
|
| Vidarabine | 1 | 1982 | 343 | 0.010 |
Why?
|
| Endorphins | 1 | 1981 | 73 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13078 | 0.010 |
Why?
|
| RNA Interference | 1 | 2009 | 2827 | 0.010 |
Why?
|
| Kinetics | 3 | 1985 | 6272 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 2060 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2001 | 195 | 0.010 |
Why?
|
| Breath Tests | 1 | 1982 | 297 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1990 | 21064 | 0.010 |
Why?
|
| Genes, Homeobox | 1 | 2001 | 287 | 0.010 |
Why?
|
| Hypnosis | 1 | 1981 | 83 | 0.010 |
Why?
|
| Genes | 1 | 1984 | 1824 | 0.010 |
Why?
|
| Pediatrics | 1 | 2015 | 3602 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1988 | 1374 | 0.010 |
Why?
|
| Diastole | 1 | 2002 | 785 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6207 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 666 | 0.010 |
Why?
|
| Thymectomy | 1 | 1981 | 200 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 596 | 0.010 |
Why?
|
| Kidney | 4 | 1994 | 7073 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1995 | 1778 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 1992 | 7840 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2005 | 855 | 0.010 |
Why?
|
| Morbidity | 1 | 2005 | 1752 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2006 | 1751 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1832 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 1983 | 385 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2001 | 528 | 0.010 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1999 | 126 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2005 | 1590 | 0.010 |
Why?
|
| Cell Division | 2 | 2003 | 4471 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20131 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1982 | 316 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 745 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1985 | 1260 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 1263 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1984 | 761 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1980 | 478 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1471 | 0.010 |
Why?
|
| Keratinocytes | 1 | 2003 | 863 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 3273 | 0.010 |
Why?
|
| Pentostatin | 3 | 1982 | 26 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2003 | 1202 | 0.010 |
Why?
|
| Genetic Testing | 2 | 2003 | 3590 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2005 | 8532 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2012 | 36542 | 0.010 |
Why?
|
| Visual Acuity | 1 | 1988 | 2672 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2007 | 2570 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9441 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18289 | 0.010 |
Why?
|
| Half-Life | 2 | 1993 | 645 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2014 | 3785 | 0.010 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 1979 | 131 | 0.010 |
Why?
|
| Thiazoles | 1 | 2005 | 1529 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 3585 | 0.010 |
Why?
|
| Choroid Neoplasms | 1 | 1979 | 175 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1978 | 240 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 407 | 0.010 |
Why?
|
| Neurilemmoma | 1 | 1983 | 522 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2003 | 1143 | 0.010 |
Why?
|
| Retina | 2 | 1979 | 2648 | 0.010 |
Why?
|
| Testis | 1 | 1981 | 781 | 0.010 |
Why?
|
| Cause of Death | 1 | 2008 | 3710 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1981 | 952 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 1984 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 511 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 238 | 0.010 |
Why?
|
| Fetus | 1 | 1984 | 1878 | 0.010 |
Why?
|
| Antigens | 1 | 1982 | 1438 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1982 | 483 | 0.010 |
Why?
|
| Adenosine | 1 | 1981 | 807 | 0.010 |
Why?
|
| Lipoprotein Lipase | 1 | 1997 | 132 | 0.010 |
Why?
|
| Acupuncture Therapy | 1 | 1981 | 466 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 1884 | 0.010 |
Why?
|
| Apolipoprotein B-100 | 1 | 1997 | 157 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 2924 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2844 | 0.010 |
Why?
|
| Topotecan | 1 | 1996 | 130 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 3427 | 0.010 |
Why?
|
| Meninges | 1 | 1978 | 201 | 0.010 |
Why?
|
| Membrane Glycoproteins | 2 | 1997 | 3690 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1984 | 3597 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1997 | 304 | 0.010 |
Why?
|
| Leukemic Infiltration | 1 | 1995 | 47 | 0.010 |
Why?
|
| Choroid | 1 | 1978 | 352 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 384 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 2716 | 0.010 |
Why?
|
| Diarrhea | 1 | 1982 | 1315 | 0.010 |
Why?
|
| Dimerization | 1 | 1996 | 880 | 0.010 |
Why?
|
| Optic Nerve Diseases | 1 | 1979 | 342 | 0.010 |
Why?
|
| Antigens, Differentiation | 2 | 1988 | 919 | 0.010 |
Why?
|
| Autopsy | 1 | 1979 | 1012 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 1981 | 634 | 0.010 |
Why?
|
| Immunotherapy | 2 | 1983 | 4752 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 561 | 0.010 |
Why?
|
| Factor VIII | 1 | 1997 | 347 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 4188 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4903 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 1372 | 0.010 |
Why?
|
| Reoperation | 1 | 1985 | 4309 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1981 | 1175 | 0.010 |
Why?
|
| Reference Values | 2 | 1997 | 4911 | 0.010 |
Why?
|
| Gingivitis | 1 | 1995 | 125 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 1567 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2423 | 0.010 |
Why?
|
| Glioma | 2 | 1996 | 3493 | 0.010 |
Why?
|
| Optic Nerve | 1 | 1978 | 568 | 0.010 |
Why?
|
| Dental Plaque | 1 | 1995 | 214 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1999 | 1332 | 0.010 |
Why?
|
| Radiography | 1 | 1985 | 6941 | 0.010 |
Why?
|
| Analgesics | 1 | 1981 | 1057 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 2997 | 0.010 |
Why?
|
| Hypophysectomy | 1 | 1994 | 113 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2910 | 0.010 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1994 | 88 | 0.010 |
Why?
|
| Pregnancy | 2 | 1987 | 30215 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 2412 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 5196 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1994 | 187 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 5873 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1977 | 691 | 0.010 |
Why?
|
| Antibodies | 1 | 1981 | 2415 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 3088 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 9355 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1990 | 6360 | 0.010 |
Why?
|
| Lung | 1 | 1991 | 10031 | 0.010 |
Why?
|
| Insurance, Life | 1 | 1992 | 14 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1995 | 12966 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1997 | 866 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3430 | 0.010 |
Why?
|
| Microcirculation | 1 | 1997 | 1279 | 0.010 |
Why?
|
| Los Angeles | 1 | 1992 | 244 | 0.010 |
Why?
|
| Cats | 2 | 1984 | 972 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1991 | 61 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 772 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 1994 | 621 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4165 | 0.010 |
Why?
|
| Brain Stem | 1 | 1996 | 854 | 0.010 |
Why?
|
| Introns | 1 | 1994 | 965 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 59506 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1985 | 12421 | 0.010 |
Why?
|
| Craniotomy | 1 | 1995 | 731 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1997 | 1811 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 992 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1994 | 1071 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1969 | 59 | 0.010 |
Why?
|
| Antibody Specificity | 2 | 1982 | 1060 | 0.010 |
Why?
|
| Immunization | 1 | 1994 | 1218 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1981 | 2513 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1996 | 1896 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 576 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1994 | 1416 | 0.000 |
Why?
|
| Triglycerides | 1 | 1997 | 2441 | 0.000 |
Why?
|
| Protein Binding | 1 | 2001 | 9297 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1527 | 0.000 |
Why?
|
| Interferon-gamma | 1 | 1997 | 3160 | 0.000 |
Why?
|
| Heart Transplantation | 1 | 2002 | 3310 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 3736 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 14745 | 0.000 |
Why?
|
| Point Mutation | 1 | 1994 | 1590 | 0.000 |
Why?
|
| Lomustine | 1 | 1988 | 60 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 189 | 0.000 |
Why?
|
| Dogs | 2 | 1984 | 3824 | 0.000 |
Why?
|
| Carmustine | 1 | 1988 | 137 | 0.000 |
Why?
|
| Leucine | 1 | 1969 | 546 | 0.000 |
Why?
|
| California | 1 | 1992 | 1436 | 0.000 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1991 | 582 | 0.000 |
Why?
|
| Age of Onset | 1 | 1995 | 3341 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1979 | 4883 | 0.000 |
Why?
|
| Macrophages | 1 | 2003 | 5771 | 0.000 |
Why?
|
| Particle Accelerators | 1 | 1988 | 173 | 0.000 |
Why?
|
| Cholesterol, LDL | 1 | 1997 | 2393 | 0.000 |
Why?
|
| Immunotoxins | 1 | 1988 | 175 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1996 | 2324 | 0.000 |
Why?
|
| Postoperative Complications | 3 | 1995 | 15794 | 0.000 |
Why?
|
| Social Support | 1 | 1996 | 2191 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 3539 | 0.000 |
Why?
|
| Deltaretrovirus | 1 | 1986 | 162 | 0.000 |
Why?
|
| Dendritic Cells | 1 | 1997 | 2746 | 0.000 |
Why?
|
| Behavior, Animal | 1 | 1994 | 1866 | 0.000 |
Why?
|
| Lipids | 1 | 1997 | 3316 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 1606 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1994 | 4618 | 0.000 |
Why?
|
| Graft Survival | 1 | 1996 | 3901 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1995 | 20680 | 0.000 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1994 | 1642 | 0.000 |
Why?
|
| Fetal Death | 1 | 1987 | 434 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 351 | 0.000 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1984 | 81 | 0.000 |
Why?
|
| Radiosurgery | 1 | 1994 | 1328 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1997 | 6408 | 0.000 |
Why?
|
| Serotyping | 1 | 1984 | 330 | 0.000 |
Why?
|
| Mathematics | 1 | 1985 | 696 | 0.000 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 3079 | 0.000 |
Why?
|
| Exercise Test | 1 | 1991 | 2184 | 0.000 |
Why?
|
| Hypoxanthines | 1 | 1982 | 35 | 0.000 |
Why?
|
| Triamcinolone | 1 | 1983 | 68 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 8105 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1982 | 164 | 0.000 |
Why?
|
| Arabinonucleosides | 1 | 1982 | 35 | 0.000 |
Why?
|
| Phorbol Esters | 1 | 1982 | 108 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 2162 | 0.000 |
Why?
|
| Pigmentation Disorders | 1 | 1983 | 105 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 3673 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 4526 | 0.000 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1981 | 9 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1983 | 289 | 0.000 |
Why?
|
| Infant, Low Birth Weight | 1 | 1987 | 869 | 0.000 |
Why?
|
| Infant Mortality | 1 | 1987 | 752 | 0.000 |
Why?
|
| Spinal Neoplasms | 1 | 1988 | 708 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1981 | 421 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1996 | 3459 | 0.000 |
Why?
|
| Abdomen | 1 | 1987 | 1133 | 0.000 |
Why?
|
| Stereoisomerism | 1 | 1981 | 613 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8927 | 0.000 |
Why?
|
| Absorption | 1 | 1979 | 242 | 0.000 |
Why?
|
| Administration, Topical | 1 | 1982 | 703 | 0.000 |
Why?
|
| Hematopoietic System | 1 | 1979 | 110 | 0.000 |
Why?
|
| Cell Separation | 1 | 1985 | 1718 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1986 | 1295 | 0.000 |
Why?
|
| Membrane Fluidity | 1 | 1978 | 67 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1981 | 298 | 0.000 |
Why?
|
| Probability | 1 | 1983 | 2475 | 0.000 |
Why?
|
| Antibodies, Bacterial | 1 | 1984 | 1473 | 0.000 |
Why?
|
| Viscosity | 1 | 1978 | 334 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1983 | 1260 | 0.000 |
Why?
|
| Rats | 1 | 1994 | 23707 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 2204 | 0.000 |
Why?
|
| Cattle | 1 | 1983 | 3801 | 0.000 |
Why?
|
| Cell Line | 2 | 1982 | 15540 | 0.000 |
Why?
|
| Infant, Premature | 1 | 1987 | 2120 | 0.000 |
Why?
|
| Spleen | 1 | 1983 | 2296 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 1994 | 7416 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1983 | 1169 | 0.000 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1979 | 1347 | 0.000 |
Why?
|
| Epitopes | 1 | 1982 | 2523 | 0.000 |
Why?
|
| Spine | 1 | 1983 | 1132 | 0.000 |
Why?
|
| DNA Replication | 1 | 1982 | 1432 | 0.000 |
Why?
|
| Aging | 1 | 1994 | 8731 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1986 | 3210 | 0.000 |
Why?
|
| Rabbits | 1 | 1979 | 4731 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1981 | 2061 | 0.000 |
Why?
|
| Liver | 1 | 1981 | 7558 | 0.000 |
Why?
|